Biopharmaceutical, Vector, Strain, Process and Product development
Nature Technology Corporation is a discovery-based bioengineering technology company, providing industry solutions for biopharmaceutical development: vectors; strains; processes; and products; including manufacturing and technology transfer. NTC specializes in services for manufacturing recombinant plasmids (gene therapeutics and DNA vaccines) and proteins.

Rational design and advanced molecular technology (Gene Self Assembly, GENSA) has led to highly effective viral and non-viral vectors, designer proteins, gene therapeutics and DNA vaccines. Advanced strain engineering technology (Genome Mass Transfer, GMT) allows specialty microbial genomes to be created from existing host strains, incorporating the genetic and regulatory elements for highest-yield production and simplified processing. Process development creates and integrates essential engineering components of upstream (fermentation) and downstream (purification) technologies, resulting in highest-purity and greatest-yield products.

Tech transfer completes the cycle by integrating production technologies into client or CMO facilities for quality manufacturing of safe and effective biologics. NTC offers highly purified custom plasmid DNA manufacturing and recombinant protein production services.
Growing Skin - Wound healing and tissue regeneration. http://science.kqed.org/quest/video/growing-skin/

Thermostable Tag (TST) protein expression system: engineering thermotolerant recombinant proteins and vaccines.
Luke, J., Carnes, A.E., Sun, P., Hodgson, C.P., Waugh, D.S., and Williams, J.A. J. Biotechnol. 151:242-50 (2011)

Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers,
Luke, J., Vincent, J.M., Du, S.X., Whalen, B., Leen, A., Hodgson, C.P., and Williams, J.A.. Gene Ther.18:334-343 (2011)

Plasmid DNA Fermentation Strain and Process-Specific Effects on Vector Yield, Quality and Transgene Expression,
Carnes, A.E., Luke, J.M., Vincent, J.M., Schukar, A., Anderson, S., Hodgson, C.P., Williams, J.A. Biotechnol. Bioeng. 108:354-63 (2011)
Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields,
Carnes, A.E., Luke, J.M., Vincent, J.M., Anderson, S., Schukar, A, Hodgson, C.P., and Williams, J.A. J. Gene Medicine 12(10):818-31. (2010)

Vector Insert-Targeted Integrative Antisense Expression System  for Plasmid Stabilization,
Luke, J.M., Carnes, A.E., Hodgson, C.P., Williams, J.A.  Mol. Biotechnol. 47:43-49, (2011)

Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza DNA Vaccine,
Luke, J.M., Simon, G.G., Soderholm, J., Errett, J.S., August, J.T., Gale, J., Hodgson, C.P., Williams, J.A. J. Virol. 85:1370-83, (2011)